During the past decade, Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 6 clinical trials were completed, i.e. on average, 75% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 2 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II" #1 sponsor was "Hoffmann-La Roche" with 4 trials, followed by "University of Heidelberg Medical Center" with 3 trials sponsored, "Celgene" with 2 trials sponsored, "Celgene Corporation" with 2 trials sponsored and "Arbeitsgemeinschaft medikamentoese Tumortherapie" with 2 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II" #1 collaborator was "Array BioPharma" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Coordinating Centre for Clinical Trials Heidelberg" with 1 trials as a collaborator, "German Cancer Research Center" with 1 trials as a collaborator and "Lymphoma Study Association" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II" are "Multiple Myeloma" (6 trials), "Giant Cell Arteritis" (1 trials), "Lymphoma, Non-Hodgkin" (1 trials), "Myelodysplastic Syndromes" (1 trials) and "Newly Diagnosed Multiple Myeloma" (1 trials). Many other conditions were trialed in "Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II" are "Drug" (14 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Dexamethasone" (3 trials), "Bortezomib" (2 trials), "Lenalidomide" (2 trials), "Placebo" (2 trials) and "Prednisone" (2 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II" are 14 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II". undefined are not yet recruiting, 1 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 10 completed trials in Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Tübingen Medizinische UNI-Klinik und Poliklinik Abt. Innere Medizin II, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".